Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 15/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549982 | 1.00 | MAPK3 (0.52) | MAPK3EGFRBTKMAPK1MAP2K1 | |
| SCHEMBL602415 | 0.85 | MAPK3 (0.40) | MAPK3EGFR | |
| SCHEMBL15938232 | 0.83 | MAPK3 (0.66) | MAPK3EGFRMAPK1MAP2K1 | |
| SCHEMBL29251292 | 0.80 | EGFR (0.55) | MAPK3EGFRBTK | |
| SCHEMBL30366835 | 0.80 | FGFR4 (0.56) | MAPK3MAPK1MAP2K1FGFR4 | |
| SCHEMBL30584603 | 0.80 | EGFR (0.55) | MAPK3EGFRBTK | |
| SCHEMBL16370812 | 0.79 | MAPK3 (0.55) | MAPK3EGFRMAPK1MAP2K1 | |
| SCHEMBL29549741 | 0.79 | MAPK3 (0.70) | MAPK3BTK | |
| SCHEMBL15938675 | 0.79 | MAPK3 (0.70) | MAPK3BTK | |
| SCHEMBL22807504 | 0.78 | MAP3K7 (0.79) | EGFRBTKMAPK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-08-25 | — | — | US | disclosed |
| EP-3986411-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | SRC, CTTN, LCK | MAPK3 273/4885EGFR 127/4885BTK 8/4885 |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | SRC, CTTN, LCK | MAPK3 273/4885EGFR 127/4885BTK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.